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Abstract
Purpose For breast cancer (BrCa) survivors, premature men-
opause can result from conventional cancer treatment. Due to
limited treatment options, survivors often turn to complemen-
tary therapies (CTs), but struggle to make informed decisions.
In this study, we identified BrCa survivors’ CT and general
information and decision-making needs related to menopausal
symptoms.
Methods The needs assessment was informed by interpretive
descriptive methodology. Focus groups with survivors
(n = 22) and interviews with conventional (n = 12) and CT
(n = 5) healthcare professionals (HCPs) were conducted at two
Canadian urban cancer centers. Thematic, inductive analysis
was conducted on the data.
Results Menopausal symptoms have significant negative im-
pact on BrCa survivors. Close to 70 % of the sample were
currently using CTs, including mind-body therapies (45.5 %),
natural health products (NHPs) and dietary therapies (31.8 %),
and lifestyle interventions (36.4 %). However, BrCa survivors
reported inadequate access to information on the safety and
efficacy of CToptions. Survivors also struggled in their efforts
to discuss CTwith HCPs, who had limited time and informa-
tion to support women in their CT decisions. Concise and
credible information about CTs was required by BrCa survi-
vors to support them in making informed and safe decisions
about using CTs for menopausal symptom management.
Conclusions High quality research is needed on the efficacy
and safety of CTs in managing menopausal symptoms follow-
ing BrCa treatment. Decision support strategies, such as pa-
tient decision aids (DAs), may help synthesize and translate
evidence on CTs and promote shared decision-making be-
tween BrCa survivors and HCPs about the role of CTs in
coping with menopause following cancer treatment.
Keywords Breast cancer .Menopause . Information needs .
Decision support . Complementary therapy
Introduction
At least 50 % of women with breast cancer (BrCa) will expe-
rience menopause as a consequence of cancer treatments
[1–4]. The abrupt onset of menopause is particularly problem-
atic for women with BrCa because they have not had an op-
portunity to acclimatize to waning levels of hormones in the
same way that occurs for women in the general population [4].
The resulting symptoms of menopause can be extremely dis-
ruptive [5, 6] and significantly reduce BrCa survivors’ quality
of life [2, 7].
Treatment options for BrCa survivors experiencing meno-
pausal symptoms are limited. Hormone replacement therapy
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(HRT) is typically avoided because of the potential risk of recur-
rence for hormone-sensitive cancer [8], despite recent research
that suggests that it should be considered on a case-by-case basis
[9]. Lifestyle changes, such as exercise and stress management,
lack strong evidence of efficacy [10–12] and have been reported
by BrCa survivors to have limited utility [13].While somewom-
en may consider pharmaceutical options, such as anti-
depressants (e.g., venlafaxine), anti-seizures (e.g., gabapentin),
or anti-hypertensives (e.g., clonidine), these medications can
have significant and unwanted side effects.
Frustrated by the limited conventional treatment options
available, BrCa survivors are motivated to search for alterna-
tives, including such complementary therapies (CTs) as acu-
puncture or natural health products (NHPs) [14–16], with at
least 25 % of survivors using NHPs to address menopausal
symptoms [17, 18]. BrCa survivors, however, have reported
difficulty finding reliable, balanced information on CToptions
[19]. Information drawn from the Internet often lacks credibil-
ity and validity [20], is overwhelming in volume and rife with
contradictory opinions [13, 21, 22]. Survivors are also frus-
trated by the lack of knowledge held by many conventional
healthcare providers (HCPs) about CTs, despite the growing
literature on the efficacy of CTs in managing menopausal
symptoms both in the general [23, 24] and BrCa [25–27]
populations. The limited time and resources available within
conventional healthcare settings to support shared decision-
making about CTs have posed further challenges for BrCa
survivors considering CTs for menopausal symptom manage-
ment [28].
These challenges highlight the need for decision support
interventions, such as patient decision aids, that will support
BrCa survivors to make informed decisions about CTs.
Decision aids (DAs) are designed to increase patient involve-
ment in the treatment decision-making process and reduce their
decisional conflict by translating clinically relevant evidence
into a patient-friendly format, while clarifying personal values
relevant to the decision [2, 29–31]. DAs are not meant to
Breplace the human element in facilitating informed choice^
[32] (p. 293), but rather aim to enhance dialogue about options
between a patient and their HCP. Without such decision sup-
port, survivors are at risk for making uninformed decisions that
can seriously impact their BrCa treatment and outcomes [33].
While DAs are available to inform menopausal [30, 34]
and cancer treatment decisions [31], an aid specific for BrCa
survivors considering CT options for menopausal symptom
management has yet to be developed. The purpose of this
study was to develop and evaluate the impact of a DA on
BrCa survivors’ decision-making behaviors and outcomes.
However, the first step in developing a DA according to the
International Patient Decision Aid Standards (IPDAS) [29] is
to conduct a needs assessment to accurately capture the treat-
ment options of interest and the information required by the
target population.
Aims of the study
The aim of this needs assessment was to identify the CTs and
related information to be included in a DA (called
MyChoices™) for BrCa survivors experiencing menopausal
symptoms. The specific objectives were to (1) identify the
most problematic menopausal symptoms experienced by
BrCa survivors, (2) assess the CT and general information
needs of BrCa survivors experiencing menopausal symptoms,
and (3) understand what BrCa survivors were currently doing
to manage menopausal symptoms.
Methods
The needs assessment was informed by qualitative descriptive
methodology [35], which privileges the simple description of
the phenomena under study.
Sample and sampling
Six focus groups were conducted with BrCa survivors recruit-
ed through the CAMEO Program1 [36], a survivorship clinic,
and support groups located in two urban cancer centers in
British Columbia and Ontario. A total of 22 women who
met the eligibility criteria participated. Eligibility included
the following: a diagnosis of stages I to IIIb BrCa in the past
5 years without recurrence, completion of primary cancer
treatment, fluency in English, and considering CTs for meno-
pausal symptom management. One woman unable to attend a
focus group participated in a one-on-one interview.
Purposeful sampling with regard to timing of diagnosis,
experience with CTs, and estrogen receptor status maximized
sample size and diversity. Women who were diagnosed with
estrogen receptor positive (ER+) BrCa were also purposefully
sampled due to the controversy that exists regarding the po-
tential role of select NHPs in stimulating a recurrence of ER+
BrCa [37, 38].
Key informant interviews were conducted with a purpose-
ful sample of 17 HCPs, including dietitians, pharmacists,
nurses, general practitioners in oncology, and medical and
radiation oncologists. Naturopathic doctors and natural health
pharmacy personnel were also interviewed as they are often
consulted by BrCa survivors about CT options [39, 40].
1 *CAMEO (Complementary Medicine Education and Outcomes) is a
research program that studies the CT decision support needs of people
living with cancer, their support persons, and HCPs, and develops pro-
grams and resources to help address those needs. CAMEO offers the
latest CT research to the conventional cancer care setting through educa-
tion courses and lectures, published documents, and individualized infor-
mation and decision support consultations.
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Data collection
The focus groups were conducted by two trained facilitators
using a structured interview guide (Table 1) informed by the
Ottawa Health Decision Centre needs assessment workbook
[41]. The focus groups encouraged BrCa survivors to discuss
their menopausal symptoms and concerns, treatment options
they had tried or were interested in, and the type of informa-
tion they needed to make informed CT decisions. The focus
groups and single interview were digitally recorded and tran-
scribed verbatim. Survivors also completed a demographic
form and the Menopausal Rating Scale (MRS) [42].
The key informants participated in 30-min interviews
that focused on how they supported BrCa survivors in
managing menopausal symptoms, including which thera-
pies they recommended, how they addressed the use of
conventional and complementary therapies, and what in-
formation they perceived to be important in making treat-
ment decisions. The interviews were digitally recorded
and transcribed verbatim.
Data analysis
Inductive thematic analysis [35] of the focus group and
key informant interview data was conducted. The tran-
scripts were read twice to develop a preliminary overview
of key themes. An initial coding scheme was developed,
which was used by two research team members (AB, LL)
to separately code two transcripts to determine if the key
concepts within the data were adequately captured. All
transcripts were coded using the qualitative software,
NVivo™. Following coding, key concepts and themes in
the data were further refined and compared across focus
groups and participants. Memoing captured coding
decisions, relationships among concepts and themes and
questions to be posed in analyzing the data.
Findings
Demographics
The sample of women (n = 22) was diagnosed between 2008
and 2010, the majority (n = 13) with ER+ stage II BrCa
(Table 2). All women had an education level greater than high
school, most self-identified as Caucasian (63.6 %), and the
majority had annual household incomes greater than
$70,000 (63.6 %).
Approximately two thirds of the HCPs had 10 years or
more oncology experience, and just over half had some train-
ing or education related to CT (52.9 %) (Table 3).
Table 1 Survivor focus group interview guide
1. Understanding menopausal symptoms and concerns
a. What are the menopausal symptoms or concerns you are dealing
with or anticipating struggling with?
2. Menopausal treatment options and information received
a. What treatments, including complementary therapies, have you tried
or are considering?
b. What information have you been given about these options?
c. Where have you sought information?
d. Do you feel you need different information?
e. Has there been conflict in the information you have been given?
f. What has the decision been like for you?
3. Information preferences
a. What kind of information would you like about managing
menopause?
b. How would you like this information presented to you?
Table 2 Characteristics of the women with breast cancer (n = 22)
Characteristic Frequency (%)
Age
30–39 years 2 (9.1)
40–49 years 9 (40.9)
50+ years 11 (50.0)
Study site
British Columbia 17 (77.2)
Ontario 5 (22.8)
Marital status
Married/common law 18 (81.8)
Not married 4 (18.2)
Education
Some college/college diploma 11 (50.0)
Bachelor degree 5 (22.7)











Stage I 3 (13.6)
Stage II 13 (59.1)
Stage III 5 (22.7)
Missing 1 (4.5)
Receptor status
Estrogen positive (ER+) 16 (72.7)
Progesterone positive (PR+) 7 (31.8)
HER2+ 5 (22.7)
Menopausal Rating Scale symptoms (moderate/severe rating)
Hot flushes, sweating 19 (86.4)
Sexual problems 19 (86.4)
Sleep problems 18 (81.8)
Depressive mood 16 (72.7)
Physical and mental exhaustion 16 (72.7)
Mean total menopausal rating (s.d.) 19.6 (7.4)
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Therapy choices
The majority of women (68.2 %) were currently using a vari-
ety of CTs to manage their menopausal symptoms (Table 4).
The most popular was mind-body therapies, which were used
by 45.5 % of the sample, followed by NHPs, which were
utilized by close to 40% of the sample. Lifestyle interventions
were also popular with 36.4 % of the sample mentioning ex-
ercise or dietary changes. Just fewer than 20 % of the women
were using prescription or over-the-counter medications, such
as anti-depressants, hormonal cream, and even HRT. Several
women were hesitant to use pharmaceutical options due to
concerns about side effects and the desire to avoid using ad-
ditional medication following their cancer treatment.
Perceptions about menopausal symptoms
A key finding was that some women were not aware their
symptoms were menopause, induced by their cancer treat-
ment—and not a temporary, remediable effect. Although
many of the women were informed that their menstrual
cycles would end following treatment, they did not fully
realize the implications and meaning of the associated
physiological changes. The women were surprised by
the sudden onset and intensity of their menopausal symp-
toms. A woman with stage III BrCa described her
experience: I didn’t know I was having menopausal symptoms
frankly... I didn’t really know what to expect of chemo,
and was just talking to a friend who is about 10 years
older than me. I said, BWell, it’s bearable, but I’m doing
this and I’m doing that, you’ll never believe this!^ And
she goes, BOh, I’ve got all that.^ And it made me realize
that what I was experiencing wasn’t just solely because I
was going through chemo….^
Both the survivors and HCPs indicated that the most both-
ersome symptom was hot flashes, throughout the day and
night, which interrupted work and sleep, and caused signifi-
cant social anxiety. The women struggled to hide the lengthy,
uncomfortable flushing and associated sweating. A woman
diagnosed over 5 years ago shared her experience:
I started chemo and it threw me into immediate meno-
pause…I have extreme hot flashes. And during the sum-
mer I would have dozens every day and all night and to
the point that I just wanted to cry. I was exhausted from
just trying to get through one after another.
The reported impact of hot flashes was corroborated by sur-
vivors’ responses to the MRS, with over 85 % of women rating
hot flashes and sweating as moderate to severe. Although other
symptoms, such as sexual problems and sleep deprivation, were
Table 3 Key informant demographics (n = 17)
Characteristic Frequency (%)
Profession
Medical oncologist 2 (11.8)
Radiation oncologist 1 (5.9)




Nurse practitioner 1 (5.9)
Naturopathic doctor 3 (17.6)
Other 2 (11.8)
Study site
British Columbia 10 (58.8)
Ontario 7 (41.2)
Years worked in oncology
Less than 10 years 6 (35.3)




Table 4 Treatments currently used to manage menopausal symptoms
(n = 22)
Type of treatment Frequency (%)
Pharmaceutical options 4 (18.2)
Hormone replacement therapy 1 (4.5)
Hormone creams 2 (9.1)
Anti-depressants 4 (18.2)
Gabapentin 1 (4.5)
Vaginal moisturizer 2 (9.1)
Natural health products/food 7 (31.8)
Black cohosh 3 (13.6)
Vitamin E 2 (9.1)
Flaxseed 5 (22.7)
Soy 1 (4.5)
Passion flower 1 (4.5)
Homeopathic remedy 1 (4.5)
Traditional Chinese medicine 1 (4.5)
Reishi mushroom 1 (4.5)
Mind-body therapies 10 (45.5)
Lifestyle therapies 8 (36.4)
Other therapies 2 (9.1)
Acupuncture 1 (4.5)
Environmental changes (e.g., fan) 1 (4.5)
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also reported to be extremely disruptive, many of these symp-
toms were directly attributed to hot flashes.
Seeking treatment information
Once women recognized their symptoms were menopause-
related and not a short-term side effect of their cancer treat-
ment, many expressed uncertainty regarding which HCPs
could best answer their questions: BDo I see my oncologist?
Do I see my general practitioner (GP)?^ Several expressed
frustration with the scarcity of information about menopause
management after BrCa and the lack of knowledge among
HCPs. Some of the women who consulted their oncologist
stated their menopausal symptoms were perceived as a rela-
tively inconsequential outcome. A woman shared: B…their
purpose [oncologists] was to keep you alive, but not give
you that extra quality of life that you needed.^
Many of the HCPs described their role in helping women
make informed decisions about treating menopausal symp-
toms. They presented as having the knowledge and training
necessary to understand the latest evidence and effectively
translate that information without, as one naturopathic doctor
framed it, Bbamboozling^ individuals. However, many felt ill
equipped to recommend specific interventions due to the lack
of clinical guidelines for menopausal symptom management
following BrCa treatment. A medical oncologist explained:
There are many review articles on the topic so I would
base my decision on the most recent literature review
that I can find. We don’t have guidelines that I have seen
within the group on the management of menopausal
symptoms.
Both the survivors and HCPs commented on the inconsis-
tency among professionals regarding the management of
menopause following BrCa. According to a pharmacist, BIt’s
really going to be dependent on which physician they’re
seeing in the community.^ A lack of consistency was also
perceived among health disciplines, which left women con-
fused and frustrated. A naturopath shared:
Coming to see somebody like me and getting a different
story than what they’re getting from their oncologist and
from their [general practitioner]…they [survivors] feel
like they’re getting three different stories and they don’t
know who to believe.
Acknowledging this confusion and lack of consistency,
several HCPs confirmed that having a tool that summarized
the evidence related to different menopausal treatment op-
tions, particularly CTs, would increase their ability to support
women in the decision-making process. A general practitioner
shared:
I think it’s important for patients, but also for us because
sometimes we don’t know about these products [NHPs]
and it would be nice if we had something that we could
easily go to and say ‘Okay, this is safe…don’t worry
about that one’ and then you can [speak] with more
confidence to the patient…
Information needs related to menopausal symptom
management
Lacking decisional support from conventional HCPs, the
women became resourceful in seeking information. They
consulted friends and family members, other BrCa survivors,
the Internet, as well as pamphlets, books, journals, and med-
ical textbooks about the various treatment options available to
manage menopausal symptoms. Foremost in women’s minds
was the safety of therapies in the context of a BrCa diagnosis.
They had serious concerns that using a CTcould interfere with
their cancer treatment or promote the growth of their cancer.
This concern overrode any possible benefit offered by a ther-
apy, even when faced with highly disruptive menopausal
symptoms. A pharmacist noted, BAs soon as we really explain
to them the distant possibility that you may actually do some
harm for the BrCa, they just back off. To them that’s more
frightful.^
For the most part, however, it was the tentative and contra-
dictory nature of the available information on the efficacy and
safety of CTs that frustrated the women. Awoman shared:
I was reading what they were saying on flaxseed, going,
‘Can you just stop waffling?’ Whoever had drafted it
didn’t want to take a position, but it left you not knowing
what the hell you should do!^
In addition to being inundated by the large volume of in-
formation, the women were frustrated by the lack of conclu-
sive information, particularly regarding CTs. Another woman
commented:
I get scared because you hear soy is bad and you hear
soy might not be bad… You think something’s good,
and then you know next week it’s going to be bad so
I’ve just sort of done nothing. I’m doing acupuncture
and I find that helps and other than that I’m kind of
scared to venture into it. There’s so much information.
You get overwhelmed. Like flaxseed is supposed to be
good for BrCa, but too much can promote BrCa so you
sort of throw up your arms!
The majority of women were also frustrated by their inabil-
ity to differentiate between credible and non-credible informa-
tion sources. They struggled to determine the trustworthiness
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of information, particularly sources from the media, the
Internet, and for some, even HCPs.
I experienced a growing distrust of the whole system.
One person says something, one person says another
and [I’m] just not trusting information to the point where
I get really anxious going to see a doctor…
CT decision-making experience
The women had difficulty making definitive treatment deci-
sions, as a consequence of unmet information needs, a per-
ceived lack of decisional support, and inconsistent informa-
tion about the efficacy and safety of therapy options in man-
aging menopausal symptoms after BrCa. Some of the survi-
vors described feeling Bparalyzed^ in the decision-making
process, fearing that a CT could result in the progression or
recurrence of cancer. Awoman described her decision-making
impasse:
…I’m frozen and I don’t know what to do, what not to
do, and honestly there are so many professionals and
practitioners who you can turn to. But at the end of the
day I just find everybody so confusing because nobody
gives you the same answers as the next person…
Other survivors described themselves as making the con-
scious decision to Bdo nothing^ after an independent search
for information about CTs. Faced with limited and contradic-
tory evidence on the efficacy and safety, these women were
uncomfortable with the degree of uncertainty and potential
risk associated with many CTs. Instead, they pursued lifestyle
interventions, such as exercise or dietary changes, as a way of
coping with their menopausal symptoms. Many of the women
expressed hesitancy about using pharmaceutical drugs toman-
age their symptoms; most preferred to avoid further conven-
tional treatment after such intensive cancer treatment.
Those BrCa survivors who did use CTs to manage their hot
flashes and other menopausal symptoms engaged in a com-
plex process of seeking and confirming information about the
possible risks and benefits. These women valued not only the
advice of HCPs but also the information obtained from other
trusted individuals, such as family members. Fellow survivors
were seen as especially helpful in providing advice about the
timing of CT use, such as Bdo one thing at a time,^ and Bfinish
[conventional] treatment first.^ These women ultimately
chose a CT that they could afford, readily incorporate into
their lives, and employ over an extended period of time.
Despite the differences among the BrCa survivors regard-
ing their CT decision, all of them expressed a need for concise
and credible information about CT options to support an in-
formed decision. They wanted to be active participants in the
decision-making process and avoid a Bpaternalistic^ relation-
ship with HCPs in which their values and beliefs were not
respected.
Discussion
Our findings highlight the profound impact of menopausal
symptoms, particularly hot flashes, on the lives of BrCa sur-
vivors. The women in this study shared stories of how hot
flashes and related symptoms disrupted their daily activities,
caused significant embarrassment and discomfort, and nega-
tively impacted their quality of life. Because many survivors
were hesitant to use HRT due to their BrCa diagnosis and
avoided pharmaceutical drugs because of the potential side
effects, these women tried a variety of CT options, including
NHPs and mind-body therapies, as well as lifestyle interven-
tions. Many of the survivors, however, found the decision-
making process challenging. Not only was it difficult to obtain
information from HCPs about CTs, the information they did
receive was often contradictory in nature. Another barrier that
hampered BrCa survivors’ decision-making was the confu-
sion around which HCP was responsible for informing survi-
vors of the various treatment strategies. In the end, the women
expressed the need for concise and credible information about
the efficacy and safety of using CTs to managing menopausal
symptoms to support them in participating in a shared
decision-making process with their HCPs.
Previous research has confirmed the significant effect men-
opausal symptoms have on women following BrCa treatment
[2, 15] as well as the popularity of CTs among BrCa survivors,
particularly within the context of menopausal symptom man-
agement [17, 18, 43]. Similar to our findings, prior qualitative
research has reported BrCa survivors’ interest in CTs to arise,
in part, from their concerns about the potential side effects of
pharmaceutical treatment options [43]. Mao et al. also
highlighted the important role that physicians and family
members play in BrCa survivors’ decision-making process
related to CTs [43]. To our knowledge, however, our study
is the first to uncover the confusion experienced by women
regarding which physician to consult about their menopausal
symptoms (i.e., oncologist versus primary care physician), as
well as their frustration with the limited and contradictory
information available in conventional care settings related to
CTs. The fear expressed by women related to using a CT that
could lead to a recurrence of cancer highlights the need for
evidence-based information about the safety of CTs in the
context of BrCa survivorship. Further, our study adds to the
existing literature by including the perspective of HCPs, who
struggled to provide recommendations about menopausal
treatment options in the absence of established guidelines for
BrCa survivors. The HCPs involved in our study identified the
need for a resource that synthesized the latest research on CTs
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to allow them to provide consistent, evidence-based advice to
survivors about the efficacy and safety of various therapies in
managing menopausal symptoms.
Our study findings reflect a larger issue in the literature
regarding the long-term management of cancer survivors
and where survivorship care is best located [44]. The lack of
national or international clinical guidelines regarding meno-
pausal symptom management in women with BrCa is a sig-
nificant gap that requires immediate attention. Rigorous, well-
designed clinical research focused on CTs and menopausal
symptom management in BrCa populations is also needed to
address the growing interest by BrCa survivors in CTs. As this
body of clinical research expands, decision support interven-
tions will be required that summarize the latest evidence relat-
ed to the efficacy and safety of these therapies and translate
this knowledge to the bedside [36]. From BrCa survivors’
perspective, such interventions must provide clear treatment
recommendations to help alleviate their fear and uncertainty
and to support their participation in shared decision-making
with HCPs.
Implications for CT decision support
The challenges experienced by BrCa survivors and HCPs to
engage in informed, evidence-based discussions about CT
options for menopausal symptom management point to the
need for effective and tailored knowledge translation and de-
cision support strategies that can be easily implemented within
varied clinical settings. Patient DAs are one strategy that effi-
ciently translates evidence-based health information and sup-
port shared decision-making between individuals and their
HCP, as well as acknowledging patients’ unique beliefs and
values [31]. A patient DA would address BrCa survivors’
information needs related to CT and menopausal symptom
management by concisely summarizing what is currently
known and unknown about conventional and complementary
treatment options, account for survivors’ health and healthcare
experiences (e.g., diagnosis, severity of menopausal symp-
toms, treatment preferences), and be utilized in both oncology
and primary care settings.
Limitations
Although efforts to ensure survivor diversity within the sam-
pling process were undertaken, the composition of a largely
Caucasian, well educated, early stage (I and II) BrCa sample
limits broad applicability of the study findings. For example,
women with later stage disease (>II) may assess risk and make
decisions about the use of CTs differently than those with
earlier stage disease [45]. Purposeful sampling from two dif-
ferent urban centers, while adding some diversity, does not
include perspectives of women living in rural and remote set-
tings, where access to CTs and the influence of sociocultural
practices may differentially influence menopause manage-
ment strategies and CT choices. Patient DAs tailored to
women’s unique menopause-related CT needs and accounting
for their social context may provide an accessible and feasible
form of decision support.
Conclusion
BrCa survivors suffer profoundly from hot flashes and other
menopausal symptoms associated with cancer treatment.
Faced with limited treatment options, many women consider
CTs for relief of their symptoms. Survivors and HCPs, how-
ever, lack credible and concise information about the efficacy
and safety of CTs. High-quality clinical trials are needed that
expand the evidence base regarding the efficacy and safety of
CTs in the management of menopausal symptoms following
BrCa treatment. Patient DAs are one decision support strategy
that may help synthesize and translate research on CTs as well
as empower BrCa survivors and HCPs to engage in shared
decision-making about the full range of therapeutic options for
managing menopausal symptoms.
Acknowledgments This study was funded by the Canadian Cancer
Society (grant no. 020658). Dr. Balneaves was funded by a Canadian
Institutes of Health Research (CIHR) New Investigator award (2008–
2013), and Ms. Lambert was a recipient of a CIHR Psychosocial
Oncology Research Training Fellowship.
Open Access This article is distributed under the terms of the Creative
Commons Attribution-NonCommercial 4.0 International License (http://
creativecommons.org/licenses/by-nc/4.0/), which permits any
noncommercial use, distribution, and reproduction in any medium,
provided you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made.
References
1. Antoine C, Liebens F, Carly B, Pastijn A, Rozenberg S (2007)
Safety of alternative treatments for menopausal symptoms after
breast cancer: a qualitative systematic review. Climacteric 10:23–
26
2. Gupta P, Sturdee DW, Palin SL, Majumder K, Fear R, Marshall T,
Paterson I (2006) Menopausal symptoms in women treated for
breast cancer: the prevalence and severity of symptoms and their
perceived effects on quality of life. Climacteric 9:49–58
3. Leining MG, Gelber S, Rosenberg R, Przypyszny M, Winer EP,
Partridge AH (2006) Menopausal-type symptoms in young breast
cancer survivors. Ann Oncol 17:1777
4. Marino JL, Saunders CM, Emery LI, Green H, Doherty DA,
Hickey M (2014) Nature and severity of menopausal symptoms
and their impact on quality of life and sexual function in cancer
survivors compared with women without a cancer history.
Menopause 21:267–274
5. Crandall C, Petersen L, Ganz PA, Greendale GA (2004)
Association of breast cancer and its therapy with menopause-
related symptoms. Menopause 11:519–530
Support Care Cancer (2016) 24:4567–4575 4573
6. Harris PF, Remington PL, Trentham-Dietz A, Allen CI, Newcomb
PA (2002) Prevalence and treatment of menopausal symptoms
among breast cancer survivors. J Pain SymptomManag 23:501–509
7. Dailey RK, Neale AV, Northrup J, West P, Schwartz KL (2003)
Herbal product use and menopause symptom relief in primary care
patients: a MetroNet study. J Women’s Health 12:633–641
8. Beral V, Banks E, Reeves G, Bull D (2003) Breast cancer and
hormone-replacement therapy: the Million Women Study. Lancet
362:1330–1331
9. Fahlen M, Fornander T, Johansson H, Johansson U, Rutqvist LE,
Wilking N, von Schoultz E (2013) Hormone replacement therapy
after breast cancer: 10 year follow up of the Stockholm randomised
trial. Eur J Cancer 49:52–59
10. Daley A, Stokes-Lampard H, Thomas A, MacArthur C (2014)
Exercise for vasomotor menopausal symptoms. Cochrane
Database Syst Rev 11:CD006108
11. Innes KE, Selfe TK, Vishnu A (2010) Mind-body therapies for
menopausal symptoms: a systematic review. Maturitas 66:135–149
12. Morrow PK, Mattair DN, Hortobagyi GN (2011) Hot flashes: a
review of pathophysiology and treatment modalities. Oncologist
16:1658–1664
13. Armitage GD, Suter E, Verhoef MJ, Bockmuehl C, Bobey M
(2007) Women’s needs for CAM information to manage meno-
pausal symptoms. Climacteric 10:215–224
14. Daley A,MacArthur C,McManusR, Stokes-LampardH,Wilson S,
Roalfe A, Mutrie N (2006) Factors associated with the use of com-
plementary medicine and non-pharmacological interventions in
symptomatic menopausal women. Climacteric 9:336
15. Hunter MS, Grunfeld EA, Mittal S, Sikka P, Ramirez AJ, Fentiman
I, Hamen H (2004) Menopausal symptoms in women with breast
cancer: prevalence and treatment preferences. Psychooncology 13:
769–778
16. van der Sluijs CP, Bensoussan A, Liyanage L, Shah S (2007)
Women’s health during mid-life survey: the use of complementary
and alternative medicine by symptomatic women transitioning
through menopause in Sydney. Menopause 14:397
17. Buettner C, Kroenke CH, Phillips RS, Davis RB, Eisenberg DM,
Holmes MD (2006) Correlates of use of different types of comple-
mentary and alternative medicine by breast cancer survivors in the
nurses’ health study. Breast Cancer Res Treat 100:219
18. Matthews AK, Sellergren SA, Huo D, List M, Fleming G (2007)
Complementary and alternative medicine use among breast cancer
survivors. J Altern Complement Med 13:555–562
19. Suter E, Verhoef MJ, Bockmuehl C, Forest N, Bobey M, Armitage
GD (2007) Inquiring minds: women’s approaches to evaluating
complementary and alternative therapies for menopausal symp-
toms. Can Fam Physician 53:84–90
20. Pilkington K, Gamst A, Liu I, Ostermann T, Pinto D, Richardon J
(2011) The International Collaboration on Complementary Therapy
Resources (ICCR): working together to improve online CAM in-
formation. J Altern Complement Med 17:647–653
21. Légaré F, Stacey D, Dodin S, O'Connor A, Richer M, Griffiths F,
LeBlanc A, Rousseau JL, Tapp S (2007)Women’s decision making
about the use of natural health products at menopause: a needs
assessment and patient decision aid. J Altern Complement Med
13:741–749
22. Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, Miller J,
Nicolaidis C, Walker M, Humphrey L (2006) Nonhormonal thera-
pies for menopausal hot flashes: systematic review and meta-anal-
ysis. JAMA 295:2057–2071
23. Chen MN, Lin CC, Liu CF (2015) Efficacy of phytoestrogens for
menopausal symptoms: a meta-analysis and systematic review.
Climacteric 18:260–269
24. Chiu HY, Pan CH, Shyu YK, Han BC, Tsai PS (2015) Effects of
acupuncture on menopause-related symptoms and quality of life in
women in natural menopause: a meta-analysis of randomized con-
trolled trials. Menopause 22:234–244
25. Bokmand S, Flyger H (2013) Acupuncture relieves menopausal
discomfort in breast cancer patients: a prospective, double blinded,
randomized study. Breast 22:320–323
26. Rostock M, Fischer J, Mumm A, Stammwitz U, Saller R, Bartsch
HH (2011) Black cohosh (Cimicifuga racemosa) in tamoxifen-
treated breast cancer patients with climacteric complaints—a pro-
spective observational study. Gynecol Endocrinol 27:844–848
27. Walker EM, Rodriguez AI, Kohn B, Ball RM, Pegg J, Pocock JR,
Nunez R, Peterson E, Jakary S, Levine RA (2010) Acupuncture
versus venlafaxine for the management of vasomotor symptoms
in patients with hormone receptor-positive breast cancer: a random-
ized controlled trial. J Clin Oncol 28:634–640
28. Balneaves LG, Truant TL, Kelly M, Verhoef MJ, Davison BJ
(2007) Bridging the gap: decision-making processes of women
with breast cancer using complementary and alternative medicine
(CAM). Support Care Cancer 15:973–983
29. Elwyn G, O'Connor A, Stacey D, Volk R, Edwards A, Coulter A,
Thomson R, Barratt A, Barry M, Bernstein S (2006) Developing a
quality criteria framework for patient decision aids: online interna-
tional Delphi consensus process. Br Med J 333:417
30. Légaré F, Dodin S, Stacey D, LeBlanc A, Tapp S (2008) Patient
decision aid on natural health products for menopausal symptoms:
randomized controlled trial. Menopause Int 14:105–110
31. Stacey D, Legare F, Col NF, Bennett CL, Barry MJ, Eden KB,
Holmes-Rovner M, Llewellyn-Thomas H, Lyddiatt A, Thomson
R, Trevena L, Wu JH (2014) Decision aids for people facing health
treatment or screening decisions. Cochrane Database Syst Rev 1:
CD001431
32. Woolf SH, Chan ECY, Harris R, Sheridan SL, Braddock CH III,
Kaplan RM, Krist A, O'Connor AM, Tunis S (2005) Promoting
informed choice: transforming health care to dispense knowledge
for decision making. Ann Intern Med 143:293–300
33. Légaré F, Ratte S, Stacey D, Kryworuchko J, Gravel K, Graham ID,
Turcotte S (2014) Interventions for improving the adoption of
shared decision making by healthcare professionals. Cochrane
Database Syst Rev 9:CD006732
34. O'Connor AM, Tugwell P, Wells GA, Elmslie T, Jolly E,
Hollingworth G, McPherson R, Bunn H, Graham I, Drake E
(1998) A decision aid for women considering hormone therapy
after menopause: decision support framework and evaluation.
Patient Educ Couns 33:267–367 279
35. Sandelowski M (2000) Whatever happened to qualitative descrip-
tion? Res Nurs Health 23:334–340
36. Balneaves LG, Truant TL, Verhoef MJ, Ross B, Porcino AJ, Wong
M, Brazier AS (2012) The Complementary Medicine Education
and Outcomes (CAMEO) program: a foundation for patient and
health professional education and decision support programs.
Patient Educ Couns 89:461–466
37. de Lemos ML (2001) Effects of soy phytoestrogens genistein and
daidzein on breast cancer growth. Ann Pharmacother 35:1118–1121
38. Walji R, Boon H, Guns E, Oneschuk D, Younus J (2007) Black
cohosh (Cimicifuga racemosa [L.] Nutt.): safety and efficacy for
cancer patients. Support Care Cancer 15:913–921
39. Balneaves LG, Bottorff JL, Hislop TG, Herbert C (2006) Levels of
commitment: exploring complementary therapy use by women
with breast cancer. J Altern Complement Med 12:459–466
40. Standish LJ, Greene K, Greenlee H, Kim JG, Grosshans C (2002)
Complementary and alternative medical treatment of breast cancer:
a survey of licensed North American naturopathic physicians.
Altern Ther Health Med 8(74–6):78–81
41. Jacobsen MJ, O’Connor A (2006) Population needs assessment: a
workbook for assessing patients’ and practitioners’ decision mak-
ing needs. http://decisionaid.ohri.ca/docs/implement/Population_
Needs.pdf. Accessed 11/15 2007.
4574 Support Care Cancer (2016) 24:4567–4575
42. Schneider HP, Heinemann LA, Rosemeier HP, Potthoff P, Behre
HM (2000) The Menopause Rating Scale (MRS): reliability of
scores of menopausal complaints. Climacteric 3:59–64
43. Mao JJ, Leed R, BowmanMA, Desai K, BrambleM, Armstrong K,
Barg F (2012) Acupuncture for hot flashes: decision making by
breast cancer survivors. J Am Board Fam Med 25:323–332
44. Rowland JH (2011) Cancer survivorship plans: a paradigm shift in the
delivery of quality cancer care. In: FeuersteinM, Ganz PA (eds) Health
services for cancer survivors. Springer, New York, pp. 169–185
45. Truant TL, Porcino AJ, Ross BC, Wong ME, Hilario CT (2013)
Complementary and alternative medicine (CAM) use in advanced
cancer: a systematic review. J Support Oncol 11:105–113
Support Care Cancer (2016) 24:4567–4575 4575
